Health IT

Developer of digital respiratory test sees scope for other diseases

The developer of a digital medical device that tests for different respiratory illnesses, such as […]

The developer of a digital medical device that tests for different respiratory illnesses, such as flu A and B strains and strep A, sees additional scope for the respiratory test as a testing platform for sexually transmitted diseases along with a broader range of infectious diseases.

The BD Veritor System, developed by Alverix and marketed by Becton, Dickinson & Co. (NYSE:BDX), has been approved for the Japanese market by the Japanese Ministry of Health, Labor and Welfare, exposing the respiratory testing device to the third-largest healthcare market in the world.

Richard Tarbox, the chief executive officer for Alverix, told MedCity News: “Alverix has begun the process of developing diagnostic tests to serve unmet needs in both the physician office and patient self-testing market segments,” Tarbox said.

The respiratory testing device  received 510(k) clearance and a Clinical Laboratory Improvement Amendments, or CLIA, waiver in the U.S. last year.

Alverix specializes in developing diagnostic testing instruments and platforms, and is a Safeguard Scientifics (NYSE:SFE) portfolio company. Becton, Dickinson markets medical devices, laboratory equipment and diagnostic products.

Tarbox said that some Alverix systems with wireless connectivity and data transmission can send patient results to any test site and it can be transmitted over wireless networks to a physician’s mobile device or EMR system, or a hospital information system.

Shares0
Shares0